CA-WILSON-SONSINI
Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jindrich Kloub has joined the firm’s antitrust and competition department as a partner in the Brussels office. Kloub’s more than 10 years of service at the European Commission’s Directorate-General for Competition and his most recent Hong Kong Competition Commission (HKCC) role illustrate the range of his enforcement agency experience and connections. His addition fortifies Wilson Sonsini’s acclaimed antitrust and competition practice in the United States and Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005164/en/
Jindrich Kloub, Partner, Wilson Sonsini (Photo: Business Wire)
Most recently, Kloub was executive director of operations at the HKCC, where he was responsible for all antitrust enforcement since 2017. In this role, he oversaw numerous precedent-setting investigations, including one that led to the HKCC’s first abuse of dominance enforcement action, as well as its first enforcement outcomes involving resale price maintenance, digital markets, leniency, settlements, commitments, director disqualifications and compliance remedies.
Kloub also has substantial international antitrust and competition policy experience. For example, in addition to leading the development of a fining methodology and cooperation and commitments policies, he oversaw major revisions to the HKCC’s leniency guidelines, which have been described within the private antitrust and competition bar as a world-class policy.
Before joining the HKCC, Kloub worked as an attorney at the European Commission’s Directorate-General for Competition (DG COMP) for more than a decade. During that time, he conducted numerous international cartel investigations, including major international cartel investigations in the financial services sector involving LIBOR and Forex benchmark rates.
“Because Hong Kong’s competition law was based on EU competition law, Jindrich has worked at two enforcement agencies that are highly engaged in monitoring and enforcing competition and antitrust laws of importance to our clients,” said Doug Clark, managing partner, Wilson Sonsini. “Jindrich’s enforcement and policy experience is the ideal combination to complement our already highly regarded antitrust and competition practice. We’re very excited to welcome him to the firm.”
Kloub’s addition comes just over a year and a half after Wilson Sonsini announced that Brent Snyder was joining the firm’s antitrust and competition practice on March 1, 2021. Snyder also joined the firm from the HKCC, having served as its CEO from 2017 through 2020.
“I’m pleased to be joining Wilson Sonsini’s accomplished competition and antitrust team, and excited about my role in helping the firm continue to expand its impressive, global practice and presence in Europe,” said Kloub. “This position not only gives me a chance to apply my enforcement and policy experience to help clients manage matters in both Europe and the U.S., but it’s also an exciting opportunity to work with Wilson Sonsini’s impressive range of clients.”
“Jindrich’s addition to our Brussels office further demonstrates Wilson Sonsini’s growing presence and strong brand in Europe – especially within the complex and constantly changing digital regulatory framework that impacts both antitrust and data protection,” said Cedric Burton, managing partner of Wilson Sonsini’s Brussels office. “Our growing team will be able to offer a new level of service and expertise on the ground to our clients within the European Union.”
Kloub earned his Master of Laws from Charles University School of Law in Prague in 2003 and his LL.M. from Columbia Law School in 2009. He has served as a visiting professor of competition law at Lille’s Catholic University for more than a decade, spoken widely at international conferences, and written numerous articles on competition law.
About Wilson Sonsini Goodrich & Rosati
For more than 60 years, Wilson Sonsini’s services and legal disciplines have focused on serving the principal challenges faced by the management and boards of directors of business enterprises. The firm is nationally recognized as a leading provider to growing and established clients seeking legal counsel to complete sophisticated corporate and technology transactions; manage governance and enterprise-scale matters; assist with intellectual property development, protection, and IP-driven transactions; represent them in contested disputes; and/or advise them on antitrust or other regulatory matters. With deep roots in Silicon Valley, Wilson Sonsini has 19 offices in technology and business hubs worldwide. For more information, please visit www.wsgr.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005164/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ
Safe Software Recognized as a Niche Player in 2025 Gartner® Magic Quadrant™ for Data Integration Tools15.12.2025 12:00:00 CET | Press release
Safe Software named for the 6th consecutive time in Gartner® Magic Quadrant™ Safe Software, a global leader in data integration and transformation, has once again been recognized in the 2025 Gartner® Magic Quadrant™ for Data Integration Tools, marking the sixth consecutive year the company has been included in this prestigious report. Safe Software’s FME Platform has evolved well beyond its geospatial roots to become the only All-Data, Any-AI Integration Platform, empowering organizations worldwide to connect all data, applications, and AI technologies anywhere, at any scale, and with complete flexibility. With a community of more than 200,000 enthusiastic users and 25,000+ organizations in over 125 countries, FME continues to redefine data integration by delivering a no-code enterprise solution that unifies data movement, automation, and AI connectivity. “Our continued recognition reflects the trust of our customers and the innovation of our team,” said Don Murray, CEO and Co-Founder
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe15.12.2025 10:00:00 CET | Press release
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreementwithOtsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercializedonidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is c
BitGo sikrer OCC-godkendelse til konvertering til føderalt chartret National Trust Bank13.12.2025 02:12:00 CET | Pressemeddelelse
Sætter ny standard for institutionel digital aktivinfrastruktur med samlet føderal tilsyn BitGo Holdings, Inc. (“BitGo”), virksomheden inden for digital aktivinfrastruktur, annoncerede i dag, at Office of the Comptroller of the Currency (“OCC”) godkendte virksomhedens ansøgning om at konvertere BitGo Trust Company, Inc., et trustselskab registreret i South Dakota, til en nationalbank ved navn BitGo Bank & Trust, National Association (N.A.). Med dagens OCC-godkendelse af konverteringen fungerer BitGos datterselskab af Trust Company nu som BitGo Bank & Trust, National Association (N.A.). BitGo Bank & Trust, N.A. vil operere under et enkelt, ensartet føderalt tilsynssystem, der gør det muligt at levere den klarhed, styring og reguleringssikkerhed, som institutioner forventer af et føderalt reguleret fiduciært selskab. Denne godkendelse styrker BitGos position som et institutionelt fundament for det moderne finansielle system, der kombinerer tilsyn på bankniveau med den sikkerhed, complian
FIA, Formula 1 Group and All 11 Race Teams Officially Sign the Ninth Concorde Agreement, Securing Strength and Stability for the Sport in Pivotal Five-Year Agreement12.12.2025 17:10:00 CET | Press release
Multi-year Concorde Governance Agreement signed by the FIA, Formula 1 Group and all 11 teams, securing the World Championship through 2030 Paves the way for a more professionalised sport and represents a new era of collaboration between the FIA and Formula 1 Group Long-term commitment enhances sporting reliability, global reach and stability for teams, fans and broadcasters The Fédération Internationale de l'Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, and Formula 1 Group, the Commercial Rights Holder, have today announced the signing of the Concorde Governance Agreement, a crucial contract defining the regulatory framework and governance terms of the FIA Formula One World Championship until 2030. This follows the announcement in March that the 2026 Commercial Concorde Agreement had been signed by all the teams and Formula 1 Group. Together, these agreements constitute the ninth Concorde Agreement, representing a m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
